Home

CRISPR Therapeutics AG - Common Shares (CRSP)

35.62
-0.52 (-1.44%)
NASDAQ · Last Trade: May 10th, 6:43 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close36.14
Open36.39
Bid35.61
Ask36.50
Day's Range35.55 - 37.34
52 Week Range30.04 - 67.88
Volume1,741,206
Market Cap2.81B
PE Ratio (TTM)-7.916
EPS (TTM)-4.5
Dividend & YieldN/A (N/A)
1 Month Average Volume2,167,817

Chart

About CRISPR Therapeutics AG - Common Shares (CRSP)

Crispr Therapeutics is a biopharmaceutical company that focuses on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing technology. The company aims to harness the potential of genetic editing to treat various conditions, including genetic disorders, cancer, and autoimmune diseases. Through a combination of innovative research and strategic collaborations, Crispr Therapeutics is dedicated to advancing its pipeline of therapies and ultimately improving patient outcomes and quality of life. Read More

News & Press Releases

3 Monster Stocks to Hold for the Next 10 Yearsfool.com
The planets are lining up for these three stocks' underlying companies.
Via The Motley Fool · May 10, 2025
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com
In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs.
Via The Motley Fool · May 8, 2025
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analystbenzinga.com
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.
Via Benzinga · May 7, 2025
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulationbenzinga.com
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Via Benzinga · May 7, 2025
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Whyfool.com
Via The Motley Fool · February 28, 2025
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Resultsbenzinga.com
Via Benzinga · May 7, 2025
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · May 7, 2025
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacksinvestors.com
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.
Via Investor's Business Daily · May 6, 2025
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giantbenzinga.com
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs.
Via Benzinga · April 30, 2025
2 Beaten-Down Stocks With Incredible Upside Potentialfool.com
Via The Motley Fool · April 30, 2025
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Yearsfool.com
Via The Motley Fool · April 20, 2025
3 Magnificent Stocks That Could Double or More by 2030fool.com
Via The Motley Fool · April 12, 2025
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?fool.com
Via The Motley Fool · April 11, 2025
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Streetfool.com
Via The Motley Fool · April 7, 2025
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com
The iconic growth investor made some interesting moves during Friday's market pullback.
Via The Motley Fool · April 7, 2025
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Robloxbenzinga.com
Via Benzinga · April 4, 2025
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in Marchfool.com
Via The Motley Fool · April 3, 2025
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Todayfool.com
Via The Motley Fool · March 31, 2025
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resignsinvestors.com
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.
Via Investor's Business Daily · March 31, 2025
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
Via MarketMinute · March 27, 2025
2 Beaten-Down Stocks to Buy on the Dipfool.com
Via The Motley Fool · March 22, 2025
2 No-Brainer Biotech Stocks to Buy Right Nowfool.com
Via The Motley Fool · March 19, 2025
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Mostbenzinga.com
Via Benzinga · March 15, 2025
Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermathbenzinga.com
On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.<
Via Benzinga · March 11, 2025
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.fool.com
Via The Motley Fool · February 28, 2025